This program sheds some light on the reality of living with advanced liposarcoma. Real patient, Norman shares just one part of his story, as he is being treated with HALAVEN® (eribulin mesylate) for his metastatic disease.
For more information, please review the Full Indication and Important Safety Information below and Full Prescribing Information at:
Mihaela Druta, MD
(Eisai consultant)
Moffitt Cancer Center, Tampa
Who is HALAVEN® (eribulin mesylate) Injection for?
HALAVEN is a prescription medicine used to treat adults with liposarcoma that cannot be treated with surgery or that has spread to other parts of the body, and who have received treatment with a certain type of anticancer medicine.
What safety information do I need to know about HALAVEN?
HALAVEN can cause serious side effects, including
• Low white blood cell count (neutropenia). This can lead to serious infections that could lead to death. Your healthcare provider will check your blood cell counts. Call your healthcare provider right away if you develop fever (temperature above 100.5°F), chills, cough, or burning or pain when you urinate, as any of these can be symptoms of infection
• Numbness, tingling, or pain in your hands or feet (peripheral neuropathy). Peripheral neuropathy is common with HALAVEN and sometimes can be severe. Tell your healthcare provider if you have new or worsening symptoms of peripheral neuropathy
• Your healthcare provider may delay or decrease your dose or stop treatment with HALAVEN if you have side effects
• Low white blood cell count (neutropenia). This can lead to serious infections that could lead to death. Your healthcare provider will check your blood cell counts. Call your healthcare provider right away if you develop fever (temperature above 100.5°F), chills, cough, or burning or pain when you urinate, as any of these can be symptoms of infection
• Numbness, tingling, or pain in your hands or feet (peripheral neuropathy). Peripheral neuropathy is common with HALAVEN and sometimes can be severe. Tell your healthcare provider if you have new or worsening symptoms of peripheral neuropathy
• Your healthcare provider may delay or decrease your dose or stop treatment with HALAVEN if you have side effects
Before you receive HALAVEN, tell your healthcare provider about all of your medical conditions, including if you
• have liver or kidney problems
• have heart problems, including a problem called congenital long QT syndrome
• have low potassium or low magnesium in your blood
• are pregnant or plan to become pregnant. HALAVEN can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with HALAVEN. Females who are able to become pregnant should use an effective form of birth control during treatment with HALAVEN and for at least 2 weeks after the final dose of HALAVEN and males should use an effective form of birth control when having sex with female partners who are able to become pregnant during treatment with HALAVEN and for 3½ months (14 weeks) after the final dose of HALAVEN
• are breastfeeding or plan to breastfeed. It is not known if HALAVEN passes into your breast milk. Do not breastfeed during treatment with HALAVEN and for 2 weeks after the final dose of HALAVEN
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of HALAVEN?
HALAVEN can cause changes in your heartbeat (called QT prolongation). This can cause irregular heartbeats. Your healthcare provider may do heart monitoring (electrocardiogram or ECG) or blood tests during your treatment with HALAVEN to check for heart problems.
The most common side effects of HALAVEN in adults with liposarcoma include tiredness, nausea, hair loss (alopecia), constipation, stomach pain, and fever.
Your healthcare provider will do blood tests before and during treatment while you are taking HALAVEN. The most common changes to blood tests in adults with liposarcoma include low white blood cell count (neutropenia) and decreased blood levels of potassium or calcium.
For more information about HALAVEN please see full Prescribing information.
Brought to you by:
@2018 Eisai Inc. All Rights Reserved. October 2018 HALA-2127